STAT

Christi Shaw, inspired by her sister’s cancer, named CEO of Kite Pharma, Gilead’s anti-cancer unit

Christi Shaw, an Eli Lilly executive, has been named the new head of Kite Pharma, which is focused on treatments that genetically engineer patients’ white blood cells to attack cancer.

Christi Shaw, until Thursday morning the executive in charge of Eli Lilly’s drug division, will become the CEO of Kite Pharma, the unit of biotechnology giant Gilead that is focused on treatments that genetically engineer patients’ white blood cells to attack cancer.

Shaw said she was inspired to take the job because that type of treatment, known as CAR-T, is what she wants to focus

You're reading a preview, sign up to read more.

More from STAT

STAT7 min readTech
One Health Care Startup At A Time, This Venture Capitalist Wants To Harness The Investing Power Of Women
“If women want specific companies in the world that address their needs, the only way to do that is for women to become the investors."
STAT4 min readSociety
Opinion: Bringing Transparency To The Notion Of Price Transparency
Transparency is not just a goal. It's also an ethic. Organizations involved in price transparency initiatives should be transparent in the ways appropriate to them.
STAT1 min read
Listen: The Serious Side Of Spit Kits, How BiTEs Leave A Mark, & Sarepta’s Sluggish Study
Is anything too weighty to be explained over the internet? Can a new spin on old technology outfox CAR-T? And does that controversial drug even work? We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. Fi